WO2007130383A3 - Compositions and treatments using pyridazine compounds and secretases - Google Patents

Compositions and treatments using pyridazine compounds and secretases Download PDF

Info

Publication number
WO2007130383A3
WO2007130383A3 PCT/US2007/010510 US2007010510W WO2007130383A3 WO 2007130383 A3 WO2007130383 A3 WO 2007130383A3 US 2007010510 W US2007010510 W US 2007010510W WO 2007130383 A3 WO2007130383 A3 WO 2007130383A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
secretases
treatments
pyridazine compounds
pyridazine
Prior art date
Application number
PCT/US2007/010510
Other languages
French (fr)
Other versions
WO2007130383A2 (en
Inventor
Martin Watterson
Eldik Linda Van
Wenhui Hu
Original Assignee
Neuromedix Inc
Martin Watterson
Eldik Linda Van
Wenhui Hu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromedix Inc, Martin Watterson, Eldik Linda Van, Wenhui Hu filed Critical Neuromedix Inc
Publication of WO2007130383A2 publication Critical patent/WO2007130383A2/en
Publication of WO2007130383A3 publication Critical patent/WO2007130383A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compositions, conjugates and methods comprising pyridazine compounds and secretase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
PCT/US2007/010510 2006-04-28 2007-04-27 Compositions and treatments using pyridazine compounds and secretases WO2007130383A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79600506P 2006-04-28 2006-04-28
US60/796,005 2006-04-28

Publications (2)

Publication Number Publication Date
WO2007130383A2 WO2007130383A2 (en) 2007-11-15
WO2007130383A3 true WO2007130383A3 (en) 2008-06-19

Family

ID=38573241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/010510 WO2007130383A2 (en) 2006-04-28 2007-04-27 Compositions and treatments using pyridazine compounds and secretases

Country Status (1)

Country Link
WO (1) WO2007130383A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018563A1 (en) 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
JP5337375B2 (en) 2004-11-02 2013-11-06 ノースウェスタン ユニバーシティ Pyridazine compounds, compositions and methods
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
MX2008013843A (en) 2006-04-28 2008-11-10 Univ Northwestern Formulations containing pyridazine compounds for treating neuroinflammatory diseases.
CA2658821C (en) 2006-07-25 2014-10-21 Cephalon, Inc. Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Fast Dissociating Dopamine 2 Receptor Antagonists
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
WO2008115381A1 (en) * 2007-03-15 2008-09-25 Schering Corporation Pyridazinone derivatives useful as glucan synthase inhibitors
FR2913886B1 (en) 2007-03-22 2012-03-02 Guerbet Sa USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007038957A1 (en) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
MX2011000043A (en) 2008-07-03 2011-02-22 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists.
WO2010012758A1 (en) 2008-07-31 2010-02-04 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
PT2361250E (en) 2008-12-22 2013-11-11 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2502909A4 (en) 2009-11-18 2013-04-03 Takeda Pharmaceutical Aminopyridine derivative
CA2788355C (en) * 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Phenyl-heteroaryl derivatives and methods of use thereof
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US9447075B2 (en) 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
US9238658B2 (en) 2011-12-06 2016-01-19 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
CA3001873A1 (en) 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurologicaldiseases
CN108697709A (en) 2015-12-10 2018-10-23 Ptc医疗公司 Method for treating Huntington disease
EA039638B1 (en) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Muscarinic receptor 4 antagonists and methods of using same
CN106831600B (en) * 2017-03-03 2019-04-12 常州沃腾化工科技有限公司 The preparation method of 3- phenyl -4-6- dichloro-pyridazine
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CN112135815A (en) 2018-03-27 2020-12-25 Ptc医疗公司 Compounds for the treatment of huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11884682B2 (en) * 2020-06-23 2024-01-30 Nanjing Immunophage Biotech Co., Ltd. Compounds and their uses as MIF inhibitors
CN112645885B (en) * 2021-01-13 2022-11-01 武汉工程大学 Iminopyridazine derivative, preparation method and application thereof, and pesticide
KR20240059614A (en) * 2021-07-21 2024-05-07 니코 테라퓨틱스, 인크. Condensed pyridazine compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
WO2006044497A2 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRAFT JEFFREY M ET AL: "Aminopyridazines attenuate hippocampus-dependent Behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation", JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 24, no. 1, 2004, pages 115 - 122, XP002476339, ISSN: 0895-8696 *
FARLOW M R: "Utilizing combination therapy in the treatment of Alzheimer's disease", EXPERT REVIEW OF NEUROTHERAPEUTICS 200409 GB, vol. 4, no. 5, September 2004 (2004-09-01), pages 799 - 808, XP009098699, ISSN: 1473-7175 *
RANAIVO H R ET AL: "Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 26, no. 2, 11 January 2006 (2006-01-11), pages 662 - 670, XP002457580, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
WO2007130383A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006099379A3 (en) Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2006025991A3 (en) Isoindoline compounds and methods of making and using the same
TW200736253A (en) Pyridopyrazine derivatives and their use
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007120729A3 (en) Pyridyl amide t-type calcium channel antagonists
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2010001169A3 (en) Chemical compounds 251
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794442

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07794442

Country of ref document: EP

Kind code of ref document: A2